Introducing Nullity AI - Build Your AI Search Engine in 30 Seconds

Transform your documents into an intelligent search engine instantly. Get started →

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

12/12/24 4:30:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JNJ alert in real time by email

Johnson & Johnson (NYSE:JNJ) will participate in the 43^rdAnnual J.P. Morgan Healthcare Conference on Monday, January 13^th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:00 p.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48-hrs after the webcast.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212414962/en/

Get the next $JNJ alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$JNJ

Date	Price Target	Rating	Analyst
12/10/2024	$166.00	Neutral	BofA Securities
11/15/2024	$190.00	Outperform	Wolfe Research
7/23/2024	$160.00 → $150.00	Outperform → Neutral	Daiwa Securities
5/30/2024	$160.00	Neutral	Goldman
4/18/2024	$170.00	Hold → Buy	HSBC Securities
12/13/2023	$170.00 → $163.00	Overweight → Equal Weight	Wells Fargo
12/1/2023	$167.00 → $180.00	Neutral → Buy	UBS
10/5/2023	$178.00	Outperform	RBC Capital Mkts

More analyst ratings

$JNJ
Leadership Updates

Live Leadership Updates

NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Gottardis is the owner of, and has served as a consultant at, Gottardis Biotech LLC, a biopharmaceuticals and research and development consultancy firm, since February 2023. Dr. Gottardi
7/15/24 8:05:00 AM ET
$JNJ
$NKGN
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Sarepta Therapeutics Set to Join S&P MidCap 400
NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For
5/29/24 5:48:00 PM ET
$JNJ
$SPGI
$SRPT
$SWAV
Biotechnology: Pharmaceutical Preparations
Health Care
Finance: Consumer Services
Finance
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
Johnson & Johnson (NYSE:JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors. "Mr. Woods is an exceptional addition to Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "Mr. Woods has an impressive career of leading and transforming healthcare systems while prioritizing the delivery of high-quality, equitable patient care. The Board looks forward to working with him as the Company continues to focus on healthcare innovation and tackling the toughest health challenges." "It is an honor to join the Johnson & Johnson Board of Directors
11/30/23 4:30:00 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Johnson & Johnson (NYSE:JNJ) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:00 p.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48-hrs after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20241212414962/en/
12/12/24 4:30:00 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of
12/10/24 8:00:00 AM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options
Abstracts presented at ASH 2024 provide insight into the patient experience given the unpredictable nature of wAIHA, a rare autoantibody disease, and the uncertainty of current treatment approaches used to manage the condition There are no FDA-approved therapies indicated for wAIHA, and patients living with this condition need targeted treatment options with a proven safety and efficacy profile Johnson & Johnson is evaluating nipocalimab for the potential treatment of wAIHA in the Phase 2/3 ENERGY study, which is expected to read out in 2025 SAN DIEGO, Dec. 9, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today findings from several online abstracts and posters on patients livi
12/9/24 8:00:00 AM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care

July 21, 2023 - FDA Roundup: July 21, 2023
For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin
7/21/23 4:02:23 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals
For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not
5/5/22 4:51:11 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots
For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione
8/18/21 1:06:11 PM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care

$JNJ
Financials

Live finance-specific insights

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of
12/10/24 8:00:00 AM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2024 of $1.24 per share on the company's common stock. The dividend is payable on December 10, 2024 to shareholders of record at the close of business on November 26, 2024. The ex-dividend date is November 26, 2024. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely
10/15/24 6:25:00 AM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Johnson & Johnson Reports Q3 2024 Results
2024 Third-Quarter reported sales growth of 5.2% to $22.5 Billion with operational growth of 6.3%* and adjusted operational growth of 5.4%* 2024 Third-Quarter Earnings per share (EPS) of $1.11 decreasing by 34.3% due to a one-time special charge and acquired IPR&D. Adjusted EPS of $2.42 decreasing by 9.0%* with acquired IPR&D impacting results approximately 1,900 basis points Significant pipeline progress including approvals of TREMFYA in ulcerative colitis, RYBREVANT + LAZCLUZE in non-small cell lung cancer, and submission of an investigational device exemption for our general surgery robotic system, OTTAVA Company increases Full-Year 2024 operational sales5 guidance Company updat
10/15/24 6:20:00 AM ET
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care

Introducing Nullity AI - Build Your AI Search Engine in 30 Seconds

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $JNJ

$JNJ Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Johnson & Johnson

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

$JNJ SEC Filings

SEC Form 13F-HR filed by Johnson & Johnson

SEC Form 10-Q filed by Johnson & Johnson

Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$JNJ Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BofA Securities resumed coverage on Johnson & Johnson with a new price target

Wolfe Research initiated coverage on Johnson & Johnson with a new price target

Johnson & Johnson downgraded by Daiwa Securities with a new price target

$JNJ Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

SEC Form 4 filed by Director Woods Eugene A.

SEC Form 4 filed by Director Hewson Marillyn A

$JNJ Leadership Updates

Live Leadership Updates

NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors

Sarepta Therapeutics Set to Join S&P MidCap 400

Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors

$JNJ Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

$JNJ Press Releases

Fastest customizable press release news feed in the world

$JNJ FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news